[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  AlphaSense [@AlphaSenseInc](/creator/twitter/AlphaSenseInc) on x 24.7K followers Created: 2025-07-03 15:17:50 UTC A key debate happening right now: Based on ASCO 2025 data, what is the adoption outlook for $AZN's camizestrant in ESR1-mutated breast cancer? Some background: AstraZeneca presented positive SERENA-6 trial data for camizestrant in HR+, HER2- metastatic breast cancer patients with ESR1 mutations (ESR1M) at ASCO 2025, the annual meeting of the American Society of Clinical Oncology, held May XX to June X. Expert Insights View: Camizestrant use in ESR1M breast cancer will be strong, unhindered by testing requirements. Oncologist, June 2025 Call: “[This] is something that’s going to be practice-changing. Typically, …when you start a patient on treatment, you monitor them. You continue to follow them until there is anatomic progression of the disease, but now this particular trial is looking at molecular progression without anatomic progression. …Is it feasible? Yes, definitely. …It's basically a blood draw. Patients, they definitely want to know whether they are responding to treatment or not.” Read or listen to this expert call:  XXXXX engagements  **Related Topics** [$azns](/topic/$azns) [$azn](/topic/$azn) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/AlphaSenseInc/status/1940792103241461970)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
AlphaSense @AlphaSenseInc on x 24.7K followers
Created: 2025-07-03 15:17:50 UTC
A key debate happening right now: Based on ASCO 2025 data, what is the adoption outlook for $AZN's camizestrant in ESR1-mutated breast cancer?
Some background: AstraZeneca presented positive SERENA-6 trial data for camizestrant in HR+, HER2- metastatic breast cancer patients with ESR1 mutations (ESR1M) at ASCO 2025, the annual meeting of the American Society of Clinical Oncology, held May XX to June X.
Expert Insights View: Camizestrant use in ESR1M breast cancer will be strong, unhindered by testing requirements.
Oncologist, June 2025 Call: “[This] is something that’s going to be practice-changing. Typically, …when you start a patient on treatment, you monitor them. You continue to follow them until there is anatomic progression of the disease, but now this particular trial is looking at molecular progression without anatomic progression. …Is it feasible? Yes, definitely. …It's basically a blood draw. Patients, they definitely want to know whether they are responding to treatment or not.”
Read or listen to this expert call:
XXXXX engagements
Related Topics $azns $azn stocks healthcare